Tagrisso(osimertinib)
Tagrisso 40 MG Oral Tablet
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
Adjuvant treatment of early‑stage NSCLC: 80 mg orally once daily, with or without food, until disease recurrence, or unacceptable toxicity, or for up to 3 years.
Metastatic NSCLC: 80 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Locally advanced or metastatic NSCLC: 80 mg orally once daily administered in combination with pemetrexed and platinum-based chemotherapy, with or without food, until disease progression or unacceptable toxicity due to TAGRISSO.
drug label
Tagrisso Prescribing Information
prior authorization
Tagrisso Prior Authorization Resources
Most recent state uniform prior authorization forms
Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form
Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form
Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form
Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form
Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form
Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form
Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form
Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form
Benefits investigation
Reimbursement help (FRM)
pharmacy
Tagrisso Preferred Pharmacy
financial assistance
Tagrisso Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
Learn More
Overview
- Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
- Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
- 100% free (outside of insurance)
Patient eligibility
- HCP must enroll patient
- May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
- Typically HCP assisted enrollment (via form)
patient education
Tagrisso Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
About Tagrisso: Resectable NSCLC (EGFR+ NSCLC After Surgery)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tagrisso: Resectable NSCLC (EGFR+ NSCLC After Surgery)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Resectable NSCLC (EGFR+ NSCLC After Surgery)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Resectable NSCLC (EGFR+ NSCLC After Surgery)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Video Library: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Caregiver Resources: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
About Tagrisso: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tagrisso: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Metastatic NSCLC (Stage IV NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - English
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Filipino
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Tagalog
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Japanese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Korean
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Vietnamese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - English
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Chinese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Filipino
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Tagalog
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Japanese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Korean
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - EGFR+ NSCLC After Surgery - Vietnamese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Stage IV NSCLC - Chinese
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
people also ask
Tagrisso FAQs
How is the dosage of Tagrisso?Tagrisso is available in 2 dosages, including 40 mg Tab and 80 mg Tab
What does Tagrisso treat?Tagrisso treats Non-Small-Cell Lung Carcinoma
What is Tagrisso made of?Tagrisso contains osimertinib which is a Kinase Inhibitor
How Is Tagrisso Administered?Tagrisso is administered as a Oral Pill
What Are The Tagrisso Mechanism Of Action?Tagrisso mechanism of action is Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inducers, Cytochrome P450 3A Inhibitors, Cytochrome P450 3A4 Inducers or Kinase Inhibitors
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available